Business
Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that the results of the Phase 2 clinical study of the xanthine oxidase inhibitor (XOI) tigulixostat (R&D code: IBI128) in Chinese gout participants were presented at the 2025 Asia-Pacific League of Associatio
About this update from Innovent Biologics, Inc.
[{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, Sept. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that the results of the Phase 2 clinical study of the xanthine oxidase inhibitor (XOI) tigulixostat (R&D code: IBI128) in Chinese gout participants were presented at the 2025 Asia-Pacific League of Associations for Rheumatology (APLAR) Congress. Tigulixostat demonstrated significantly greater urate-lowering efficacy and favorable safety profiles compared to febuxostat across all dose groups. Based on these positive data, Innovent plans to initiate the Phase 3 clinical study of tigulixostat in China in the second half of 2025.","length":900,"tagName":"p"},{"type":"text","content":"The published results are based on a randomized, open-label, multicenter, parallel-group, active-controlled Phase 2 clinical study (NCT06501534) evaluating the efficacy and safety of different doses of tigulixostat in Chinese gout participants.","length":244,"tagName":"p"},{"type":"text","content":"A total of 84 participants (mean age: 37 years; mean baseline serum uric acid [sUA]: 575 μmol/L [9.6 mg/dL]; mean baseline weight: 80.7 kg) were enrolled and randomized to receive tigulixostat 50 mg, 100 mg, 200 mg or febuxostat 40 mg for 16 weeks (or 18 weeks for the tigulixostat 200 mg group). The primary endpoint was the proportion of participants achieving sUA <360 μmol/L (6 mg/dL) at Week 16.","length":403,"tagName":"p"},{"type":"text","content":"Tigulixostat demonstrated significantly greater urate-lowering efficacy compared to febuxostat across all dose groups, with a dose-dependent effect.","length":148,"tagName":"p"},{"type":"image","alt":"* P＜0.05,** P＜0.01, *** P＜0.001","displaySize":"","headline":null,"caption":"* P＜0.05,** P＜0.01, *** P＜0.001","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":290,"url":"https://media.zenfs.com/en/prnewswire.com/bcd06f63386bd8fb18cd9c5834213813"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/M2y185raipLuqdWifuPfgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUxMTtjZj13ZWJw/https://media.zenfs...